中文名称 | (33R,34S,35S,91R,92R,5S)-5-(叔丁基)-N-((1R,2R)-2-(二氟甲基)-1-(((1-甲基环丙基)磺酰基)氨基甲酰基)环丙基)-34-乙基-14,14-二氟-17-甲氧基-4,7-二氧代-2,8-二氧杂-6-氮杂-1(2,3)-喹喔啉-3(3,1)-吡咯烷-9(1,2)-环丙烷环十四烷-35-甲酰胺; 伏西瑞韦 |
---|---|
英文名称 | Voxilaprevir (Synonyms:GS-9857) |
CAS号 | 1535212-07-7 |
分子式 | C40H52F4N6O9S |
分子量 | 868.93 |
MDL | MFCD32174311 |
Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity. Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with Ki values of 0.038 nM and 0.066 nM, respectively. Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research.
© 2020-2024 凯立德生物医药技术(上海)有限公司 版权所有
沪ICP备15046197号-3
沪公网安备31011502007856号
Designed by Kuanersoft